Skip to content

Replimune Group REPL Property, plant and equipment at cost

Property, plant and equipment at cost at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Tango Therapeutics logo
Tango TherapeuticsTNGX
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's property, plant and equipment at cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's property, plant and equipment at cost?
Replimune Group (REPL) reported property, plant and equipment at cost of $29.81M in Q4 2025.
How has Replimune Group's property, plant and equipment at cost changed year-over-year?
Replimune Group's property, plant and equipment at cost increased by 13.9% year-over-year, from $26.17M to $29.81M.
What is the long-term trend for Replimune Group's property, plant and equipment at cost?
Over 4 years (2021 to 2025), Replimune Group's property, plant and equipment at cost has grown at a 28.1% compound annual growth rate (CAGR), from $10.09M to $27.14M.